GSK buys derm firm Steifel

Share this article:
GlaxoSmithKline is buying dermatology specialist Steifel for $3.6 billion.

The acquisition, announced just days after the rollout of its HIV joint venture with Pfizer, gives GSK a broadened dermatology portfolio accounting for 8% of the global market, with combined revenues estimated at $1.5 billion, and Steifel's specialty sales force.

Steifel products include Duac, for acne, Olux E for dermatitis and Soriatane for severe psoriasis, along with 15 products in late-stage development. GSK derm brands include Bactroban, Cutivate and Altabax. The GSK and Steifel brands would be combined in a global specialist group under the Steifel name, led by Steifel chairman and CEO Charles Steifel.

“As part of our strategy to grow and diversify GSK's business, we are continuing to make new investments through targeted acquisitions,” said GSK CEO Andrew Witty. “This transaction will create a new world-leading specialist dermatology business and re-energize our existing dermatology products.”

On Thursday, GSK and Pfizer announced a deal to combine their HIV businesses into a new company in which GSK will initially hold an 85% equity stake and Pfizer 15%.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...